Skip to main content

Advertisement

Table 2 KRAS and BRAF mutational status with outcomes

From: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

  KRAS (n = 67) BRAF (n = 64)
Wild-type (WT) 43 (64%) 61 (95%)
Mutant 24 (36%) 3 (5%)
Median OS WT 4.1 years 4.1 years
Median OS mutant 4.9 years p = 0.6 Not reached p = 0.1
WT vs. mutant   
   Limited response 67% vs. 67% 69% vs. 33% (1 of 3)
   Major response 14% vs. 21% 16% vs. 0%
   Complete response 19% vs. 13% p = 0.7 15% vs. 66% (2 of 3)
WT vs. mutant   
   Downstaged 42% vs. 38% 36% vs. 66% (2 of 3)
   No change or upstaged 58% vs. 63% p = 0.8 64% vs. 33% (1 of 3)
Recurrence   
   None 67% vs. 54% 62% vs. 100% (3 of 3)
   Local recurrence 12% vs. 8% 10%
   Distant recurrence 14% vs. 29% 20%
   Both local and distant 7% vs. 8% p = 0.5 8%
  1. WT: Wildtype; OS: Overall Survival